miR-122-A key factor and therapeutic target in liver disease

被引:506
作者
Bandiera, Simonetta [1 ,2 ]
Pfeffer, Sebastien [2 ,3 ]
Baumert, Thomas F. [1 ,2 ,4 ]
Zeisel, Mirjam B. [1 ,2 ]
机构
[1] Inst Rech Malad Virales & Hepat, INSERM, U1110, Strasbourg, France
[2] Univ Strasbourg, F-67000 Strasbourg, France
[3] CNRS, Inst Biol Mol & Cellulaire, UPR 9002, F-67084 Strasbourg, France
[4] Hop Univ Strasbourg, Inst Hosp Univ, Strasbourg, France
关键词
Hepatitis; HBV; HCV; miR-122; Liver disease pathogenesis; HCC; HEPATITIS-C VIRUS; MICRORNA; 122; EXPRESSION; B-VIRUS; GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; IN-VIVO; CIRCULATING MICRORNAS; CELL-PROLIFERATION; UP-REGULATION; RNA;
D O I
10.1016/j.jhep.2014.10.004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Being the largest internal organ of the human body with the unique ability of self-regeneration, the liver is involved in a wide variety of vital functions that require highly orchestrated and controlled biochemical processes. Increasing evidence suggests that microRNAs (miRNAs) are essential for the regulation of liver development, regeneration and metabolic functions. Hence, alterations in intrahepatic miRNA networks have been associated with liver disease including hepatitis, steatosis, cirrhosis and hepatocellular carcinoma (HCC). miR-122 is the most frequent miRNA in the adult liver, and a central player in liver biology and disease. Furthermore, miR-122 has been shown to be an essential host factor for hepatitis C virus (HCV) infection and an antiviral target, complementary to the standard of care using direct-acting antivirals or interferon-based treatment. This review summarizes our current understanding of the key role of miR-122 in liver physiology and disease, highlighting its role in HCC and viral hepatitis. We also discuss the perspectives of miRNA-based therapeutic approaches for viral hepatitis and liver disease. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:448 / 457
页数:10
相关论文
共 126 条
[1]   miR-34: from bench to bedside [J].
Agostini, Massimiliano ;
Knight, Richard A. .
ONCOTARGET, 2014, 5 (04) :872-881
[2]   Diversifying microRNA sequence and function [J].
Ameres, Stefan L. ;
Zamore, Phillip D. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2013, 14 (08) :475-488
[3]  
[Anonymous], ANTIVIR THER
[4]  
[Anonymous], LANCET
[5]  
[Anonymous], EMBO MOL MED
[6]  
[Anonymous], HEPATOL RES
[7]   MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib [J].
Bai, Shoumei ;
Nasser, Mohd W. ;
Wang, Bo ;
Hsu, Shu-Hao ;
Datta, Jharna ;
Kutay, Huban ;
Yadav, Arti ;
Nuovo, Gerard ;
Kumar, Pawan ;
Ghoshal, Kalpana .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (46) :32015-32027
[8]   microRNAs in diseases: from candidate to modifier genes [J].
Bandiera, S. ;
Hatem, E. ;
Lyonnet, S. ;
Henrion-Caude, A. .
CLINICAL GENETICS, 2010, 77 (04) :306-313
[9]   Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs [J].
Bartel, DP ;
Chen, CZ .
NATURE REVIEWS GENETICS, 2004, 5 (05) :396-400
[10]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29